Clinical Trial Update: Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) [Phase 3]

View source ↗

Summary

Phase 3 study of CB-183,315 in Clostridium difficile infection has completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• CB-183,315

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Clostridium Difficile Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-02-28